Skip to main content

Longeveron Inc.

corporate_fare Company Profile

Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed LGVN - Latest Insights

LGVN
Apr 17, 2026, 4:23 PM EDT
Filing Type: 424B3
Importance Score:
9
Longeveron Finalizes Resale of 30.8M Shares, Enabling Massive Dilution from Deeply Discounted Private Placement
Sentiment: Negative
View Wiseek Article
LGVN
Apr 10, 2026, 4:55 PM EDT
Source: Reuters
Importance Score:
8
Longeveron Repays Executives, Grants 750K RSUs Amid Going Concern Doubts
Sentiment: Negative
View Wiseek Article
LGVN
Apr 10, 2026, 4:49 PM EDT
Filing Type: 8-K
Importance Score:
8
Longeveron Repays Executive Pay Cuts, Grants Significant RSU Awards Amidst Financial Distress
Sentiment: Negative
View Wiseek Article
LGVN
Apr 10, 2026, 4:01 PM EDT
Filing Type: S-1
Importance Score:
9
Longeveron Registers Resale of 30.8 Million Shares from Deeply Discounted Private Placement, Exceeding Current Market Cap
Sentiment: Negative
View Wiseek Article
LGVN
Mar 25, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Longeveron Receives Nasdaq Extension to Regain Minimum Bid Price Compliance
Sentiment: Neutral
View Wiseek Article
LGVN
Mar 17, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Longeveron to Share 50% of Future FDA Priority Review Voucher Proceeds with Private Placement Investors
Sentiment: Negative
View Wiseek Article
LGVN
Mar 17, 2026, 4:01 PM EDT
Filing Type: 10-K
Importance Score:
9
Longeveron Faces Going Concern Doubt, Secures Highly Dilutive $15.9M Financing at Deep Discount Amid Nasdaq Non-Compliance
Sentiment: Negative
View Wiseek Article
LGVN
Mar 12, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
9
$15.9M Private Placement Closes for Longeveron, Potential $15M More Contingent on Milestones
Sentiment: Neutral
View Wiseek Article
LGVN
Mar 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Longeveron Secures $16.79M in Highly Dilutive Private Placement at Deep Discount, Extends Runway
Sentiment: Negative
View Wiseek Article
LGVN
Mar 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Longeveron Closes $15M Initial Tranche of $30M Dilutive Private Placement at $0.52/Share
Sentiment: Negative
View Wiseek Article
LGVN
Mar 10, 2026, 9:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Longeveron Secures Up to $30M Private Placement, Signaling Significant Dilution
Sentiment: Negative
View Wiseek Article
LGVN
Mar 09, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Longeveron Discloses Nasdaq Non-Compliance Over Missing Audit Committee Financial Expert
Sentiment: Negative
View Wiseek Article
LGVN
Mar 06, 2026, 5:59 PM EST
Filing Type: 8-K
Importance Score:
8
Longeveron Inc. Discloses Nasdaq Non-Compliance Due to Audit Committee Financial Expert Vacancy
Sentiment: Negative
View Wiseek Article
LGVN
Mar 03, 2026, 7:59 AM EST
Filing Type: PRE 14A
Importance Score:
8
Longeveron Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
LGVN
Feb 13, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
8
Longeveron Appoints New CEO, Implements Deep Cost Cuts Amidst Cash Runway Review
Sentiment: Negative
View Wiseek Article